Locatim (previously Serinucoli)

RSS

Locatim, oral solution for neonatal calves less than 12 hours of age

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 18/07/2013

Authorisation details

Product details
Name
Locatim (previously Serinucoli)
Agency product number
EMEA/V/C/000041
Active substance
Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin
International non-proprietary name (INN) or common name
Locatim, oral solution for neonatal calves less than 12 hours of age
Species
Calves, neonatal less than 12 hrs of age
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI02AT01
Publication details
Marketing-authorisation holder
Biokema Anstalt
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
28/03/1999
Contact address
Pflugstrasse 12
Fürstentum
9490 Vaduz
Liechtenstein

Product information

12/06/2013 Locatim (previously Serinucoli) - EMEA/V/C/000041 - II/0012

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

IMMUNOLOGICALS FOR BOVIDAE

Therapeutic indication

Reduction of mortality caused by enterotoxicosis associated with E. coli F5 (K99) adhesin during the first days of life as a supplement to colostrum from the dam.

Assessment history

How useful was this page?

Add your rating